S&P 500   3,324.54 (+0.11%)
DOW   29,219.18 (+0.08%)
QQQ   224.08 (+0.36%)
AAPL   318.80 (+0.70%)
FB   221.82 (+0.17%)
MSFT   165.98 (-0.31%)
GOOGL   1,488.15 (+0.40%)
AMZN   1,890.41 (-0.08%)
CGC   24.14 (-0.04%)
NVDA   250.48 (+1.02%)
BABA   223.10 (+0.38%)
MU   59.07 (+0.17%)
GE   11.43 (-1.97%)
TSLA   566.58 (+3.54%)
AMD   51.48 (+0.84%)
T   39.12 (+1.56%)
ACB   2.04 (+1.49%)
F   9.15 (-0.65%)
NFLX   325.33 (-3.78%)
PRI   126.72 (+0.25%)
BAC   34.39 (+0.38%)
DIS   144.30 (+0.52%)
GILD   63.43 (+1.26%)
S&P 500   3,324.54 (+0.11%)
DOW   29,219.18 (+0.08%)
QQQ   224.08 (+0.36%)
AAPL   318.80 (+0.70%)
FB   221.82 (+0.17%)
MSFT   165.98 (-0.31%)
GOOGL   1,488.15 (+0.40%)
AMZN   1,890.41 (-0.08%)
CGC   24.14 (-0.04%)
NVDA   250.48 (+1.02%)
BABA   223.10 (+0.38%)
MU   59.07 (+0.17%)
GE   11.43 (-1.97%)
TSLA   566.58 (+3.54%)
AMD   51.48 (+0.84%)
T   39.12 (+1.56%)
ACB   2.04 (+1.49%)
F   9.15 (-0.65%)
NFLX   325.33 (-3.78%)
PRI   126.72 (+0.25%)
BAC   34.39 (+0.38%)
DIS   144.30 (+0.52%)
GILD   63.43 (+1.26%)
S&P 500   3,324.54 (+0.11%)
DOW   29,219.18 (+0.08%)
QQQ   224.08 (+0.36%)
AAPL   318.80 (+0.70%)
FB   221.82 (+0.17%)
MSFT   165.98 (-0.31%)
GOOGL   1,488.15 (+0.40%)
AMZN   1,890.41 (-0.08%)
CGC   24.14 (-0.04%)
NVDA   250.48 (+1.02%)
BABA   223.10 (+0.38%)
MU   59.07 (+0.17%)
GE   11.43 (-1.97%)
TSLA   566.58 (+3.54%)
AMD   51.48 (+0.84%)
T   39.12 (+1.56%)
ACB   2.04 (+1.49%)
F   9.15 (-0.65%)
NFLX   325.33 (-3.78%)
PRI   126.72 (+0.25%)
BAC   34.39 (+0.38%)
DIS   144.30 (+0.52%)
GILD   63.43 (+1.26%)
S&P 500   3,324.54 (+0.11%)
DOW   29,219.18 (+0.08%)
QQQ   224.08 (+0.36%)
AAPL   318.80 (+0.70%)
FB   221.82 (+0.17%)
MSFT   165.98 (-0.31%)
GOOGL   1,488.15 (+0.40%)
AMZN   1,890.41 (-0.08%)
CGC   24.14 (-0.04%)
NVDA   250.48 (+1.02%)
BABA   223.10 (+0.38%)
MU   59.07 (+0.17%)
GE   11.43 (-1.97%)
TSLA   566.58 (+3.54%)
AMD   51.48 (+0.84%)
T   39.12 (+1.56%)
ACB   2.04 (+1.49%)
F   9.15 (-0.65%)
NFLX   325.33 (-3.78%)
PRI   126.72 (+0.25%)
BAC   34.39 (+0.38%)
DIS   144.30 (+0.52%)
GILD   63.43 (+1.26%)
Log in

NYSE:NVO - Novo Nordisk A/S Stock Price, Forecast & News

$61.34
+0.20 (+0.33 %)
(As of 01/22/2020 03:43 PM ET)
Today's Range
$61.08
Now: $61.34
$61.65
50-Day Range
$56.53
MA: $58.14
$62.39
52-Week Range
$46.10
Now: $61.34
$62.69
Volume836,810 shs
Average Volume1.01 million shs
Market Capitalization$145.25 billion
P/E Ratio25.04
Dividend Yield1.04%
Beta0.6
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone45-4444-8888

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.72 billion
Cash Flow$2.75 per share
Book Value$3.24 per share

Profitability

Net Income$5.91 billion

Miscellaneous

Employees43,202
Outstanding Shares2,368,000,000
Market Cap$145.25 billion
Next Earnings Date2/7/2020 (Estimated)
OptionableOptionable

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Investors looking for the best way to potentially double their money in 2020 -- regardless of whether the overall markets are up or down -- should look no further than these 3 unique stocks.

This Special Report reveals the names of these stocks and provides everything you need to invest right away.

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a Semi-Annual dividend on Friday, August 9th. Investors of record on Monday, August 19th will be paid a dividend of $0.318 per share on Tuesday, August 27th. The ex-dividend date is Friday, August 16th. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S announced that its Board of Directors has authorized a stock repurchase program on Friday, February 2nd 2018, which allows the company to buyback shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company's management believes its stock is undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings data on Friday, November, 1st. The company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.02. The company had revenue of $4.51 billion for the quarter, compared to analysts' expectations of $4.55 billion. Novo Nordisk A/S had a return on equity of 75.48% and a net margin of 32.44%. View Novo Nordisk A/S's Earnings History.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for Novo Nordisk A/S.

What price target have analysts set for NVO?

12 brokers have issued 1-year target prices for Novo Nordisk A/S's stock. Their forecasts range from $48.61 to $400.00. On average, they expect Novo Nordisk A/S's share price to reach $181.58 in the next year. This suggests a possible upside of 196.0% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.

What is the consensus analysts' recommendation for Novo Nordisk A/S?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

Has Novo Nordisk A/S been receiving favorable news coverage?

News coverage about NVO stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novo Nordisk A/S earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Novo Nordisk A/S.

Who are some of Novo Nordisk A/S's key competitors?

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Johnson & Johnson (JNJ), AT&T (T), NVIDIA (NVDA), Starbucks (SBUX), Cisco Systems (CSCO) and Alibaba Group (BABA).

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 53)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 59)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 47)
  • Mr. Lars Green, Exec. VP and Head of Bus. Services & Compliance (Age 52)
  • Mr. Ole F. Ramsby, Sr. VP & Gen. Counsel of Legal Affairs

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.01%), Janney Montgomery Scott LLC (0.00%), Atwater Malick LLC (0.00%), Commerzbank Aktiengesellschaft FI (0.00%), Smithbridge Asset Management Inc. DE (0.00%) and OmniStar Financial Group Inc. (0.00%). View Institutional Ownership Trends for Novo Nordisk A/S.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Commerzbank Aktiengesellschaft FI, First Hawaiian Bank, Scout Investments Inc., Norris Perne & French LLP MI, Smithbridge Asset Management Inc. DE, Norman Fields Gottscho Capital Management LLC and OmniStar Financial Group Inc.. View Insider Buying and Selling for Novo Nordisk A/S.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was purchased by a variety of institutional investors in the last quarter, including Chemung Canal Trust Co., Janney Montgomery Scott LLC, We Are One Seven LLC, Calamos Advisors LLC, Ingalls & Snyder LLC, SeaCrest Wealth Management LLC, Atwater Malick LLC and Huntington National Bank. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $61.34.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $145.25 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.View Additional Information About Novo Nordisk A/S.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  331 (Vote Outperform)
Underperform Votes:  434 (Vote Underperform)
Total Votes:  765
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: Gap Down Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel